ARTICLE | Company News
Spectrum Pharmaceuticals cancer news
October 15, 2012 7:00 AM UTC
Spectrum said that the U.S. Patent and Trademark Office (PTO) extended by five years U.S. Patent No. 6,028,071 covering cancer drug Folotyn pralatrexate. The extension postpones the original July 16...